

Medication-Assisted Treatment


Buprenorphine Waiver Training

8:00am - 12:00pm, Friday, Sept. 21, 2018

Oklahoma State Medical Association
(OSMA) 313 NE 50th Street, OKC, OK 73105

Brought to you by the Osteopathic Founders Foundation,
Oklahoma Department of Mental Health and Substance Abuse Services,
and the Providers Clinical Support System.

Non Profit Org
U. S. Postage
PAID
Tulsa, OK
Permit No. 2166

 osteopathic
FOUNDERS FOUNDATION
8801 South Yale, Suite 400
Tulsa, OK 74137

Medication-Assisted Treatment

Buprenorphine Waiver Training

8:00am - 12:00pm, Friday, Sept. 21, 2018



Location

OSMA
313 NE 50th St.
OKC, OK 73105
405-601-9571



Who

This course is open to Osteopathic Physicians, Allopathic Physicians, Physician Assistants and Nurse Practitioners who have a valid medical license and an active DEA number.



Cost

The course is free of charge to registrants.



Breakfast & Sign-in

Beginning at 7:30am.



Registration

Register online at
<https://osteopathicfounders.org/events/buprenorphine-9-21-18/> by September 17, 2018.

Class size is limited to the first 75 people. Questions?
Contact Steffin Baker at 918-551-7300 or
sbaker@osteopathicfounders.org.



Accreditation Statements

CME Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AAAP, Osteopathic Founders Foundation and the Oklahoma Department of Mental Health and Substance Abuse Services.

Credit Designation: American Academy of Addiction Psychiatry designates this Other activity ("Half and Half" - Half face-to-face live course and Half online course) for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of physician participation in the learning process: Credit will only be awarded for completing both the "first" and the "second" half of the training. To be awarded a maximum of 8 AMA PRA Category 1 Credits™ and a Buprenorphine Training Completion Certificate you must complete 4.25 hours of the first live half and 3.75 hours of the second enduring half and receive a minimum cumulative score of 75% on the examination. No partial credit is awarded for this training.

The Osteopathic Founders Foundation is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. The Osteopathic Founders Foundation designates this program for a maximum of 4 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician's participation in this activity.

Steps to Obtain Buprenorphine Waiver:

1. **Attend this 4 hour in-person training.**
You must stay the entire four hours to qualify. A sign-in/ sign-out will be required and you cannot miss more than 10 minutes of class time.
2. **Complete 4 hours of online training.**
After the course an email will be sent from PCSS to attendees with the link to complete the online portion. Please Note: If you are a Physician Assistant or a Nurse Practitioner you will require an additional 16 hours of online training. Training requirements can be found here <https://pcssnow.org/education-training/mat-training>.
3. **Forward Certificate of Completion to SAMHSA.**
4. **Complete and Submit a Notice of Intent Form to SAMHSA.**

Once SAMHSA has obtained all documentation, the process requires 45 days approximately.

Brought to you by the Osteopathic Founders Foundation, Oklahoma Department of Mental Health and Substance Abuse Services, and the Providers Clinical Support System. American Academy of Addiction Psychiatry is the DATA 2000 sponsor for this training.



Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government